FDA Approves Lilly's Trijardy
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Eli Lilly's new drug, Trijardy, which is expected to enhance the company's product portfolio and potentially boost its revenues. This approval marks a significant milestone for Eli Lilly, as it expands its offerings in the pharmaceutical market.
January 27, 2020 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly received FDA approval for its new drug, Trijardy, which is likely to enhance its product portfolio and potentially increase revenues.
The FDA approval of Trijardy is a positive development for Eli Lilly, as it adds a new product to their portfolio, which can lead to increased sales and revenue growth. This approval is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100